Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Cited by (434)

Items 201–300 of 434

1. Geographic Differences in Patients with Acute Myocardial Infarction in the PARADISE-MI Trial
   Jawad H. Butt, Brian Lee Claggett, Zi Michael Miao, Karola Jering, David Sim, Peter van der Meer, Mpiko Ntsekhe, Offer Amir, Myeong‐Chan Cho, Jorge Carrillo‐Calvillo et al. · 2023 · European Journal of Heart Failure
2. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients
   Patrick S. Parfrey, Steven K. Burke, Glenn Matthew Chertow, Kai‐Uwe Eckardt, Alan G. Jardine, Eldrin Foster Lewis, Wei Feng Luo, Kunihiro Matsushita, Peter Andrew McCullough, Todd Eric Minga et al. · 2023 · Kidney Medicine
3. Platelet-Mediated Thrombosis and Drug-Eluting Stents
   Juan F. Granada, Matthew J. Price, Patricia A. French, Steven R. Steinhubl, Donald E. Cutlip, Richard Clinton Becker, Susan S. Smyth, Harold L. Dauerman · 2011 · Circulation Cardiovascular Interventions
4. Antiplatelet therapy – ticagrelor
   Hugo Albert Katus, Evangelos Giannitsis · 2012 · Hämostaseologie
5. Acute Myocardial Infarction
   Akram W. Ibrahim, Thomas C. Riddell, Chandan M. Devireddy · 2014 · Critical Care Clinics
6. The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
   Robert Patrick Giugliano, Eugene Braunwald · 2012 · Journal of the American College of Cardiology
7. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes
   David S. Roffman · 2015 · Journal of Pharmacy Practice
8. Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
   Bernard John Gersh · 2012 · Yearbook of Cardiology
9. Aspirin resistance in coronary heart disease: Current understandings and strategies
   Yaling Han · 2016 · Journal of Translational Internal Medicine
10. Data-Driven and Confirmatory Subgroup Analysis in Clinical Trials
    Alex A. Dmitrienko, Ilya A. Lipkovich, Aaron L. Dane, Christoph Muysers · 2020 · Emerging topics in statistics and biostatistics
11. Pharmacokinetic/Pharmacodynamic Modeling To Predict the Antiplatelet Effect of the Ticagrelor-Loaded Self-Microemulsifying Drug Delivery System in Rats
    Young‐Guk Na, Jin‐Ju Byeon, Min‐Ki Kim, Min-Gu Han, Cheong‐Weon Cho, Jong-Suep Baek, Hong-Ki Lee, Young Geun Shin · 2020 · Molecular Pharmaceutics
12. Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System
    James C. Coons, Carlo J. Iasella, Tyler Chanas, Nan Wang, Kiersten Williams, Anthony M. Boyd, John Lyons, Jamie Eckardt, Lindsey Rihtarchik, Alison Merkel et al. · 2017 · Annals of Pharmacotherapy
13. Antithrombotic Drugs
    Iqbal Jaffer, Jeffrey Ian Weitz · 2017 · Elsevier eBooks
14. Regional Variations in Clinical Trial Outcomes in Oncology
    Brooke E. Wilson, Sallie‐Anne Pearson, Michael Bernard Barton, Eitan Amir · 2022 · Journal of the National Comprehensive Cancer Network
15. Acute Coronary Syndromes
    Sukhdeep S. Basra, Salim S. Virani, David E. Paniagua, Biswajit Kar, Hani M. Jneid · 2014 · Cardiology Clinics
16. Oral antiplatelet therapy after drug-eluting stent implantation
    Roberta Rossini, Matteo Baroni, Giuseppe Musumeci, Antonello Gavazzi · 2012 · Journal of Cardiovascular Medicine
17. Novel Antiplatelet and Anticoagulant Agents in the Cardiac Care Unit
    Vaani Garg, Jonathan L. Halperin · 2013 · Cardiology Clinics
18. Dual-antiplatelet Therapy Guidelines and Implications for Perioperative Management
    Kristin M. Stawiarski, Rachna Kataria, Claudio Bravo, Pedro Villablanca, Divyanshu Mohananey, Seshasayee Narasimhan, Harish Ramakrishna · 2017 · Journal of Cardiothoracic and Vascular Anesthesia
19. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome
    Martin Orban, Steffen Maßberg, Dirk Sibbing · 2013 · Hämostaseologie
20. Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction
    Gemma Vilahur, Monika Aržanauskaitė, Pablo Sutelman, Soumaya Ben‐Aicha, Manuel Gutiérrez, Laura Casaní, Daniel Hovdal, Emily L. Ongstad, Anders Gabrielsen, Alberto Hidalgo et al. · 2024 · European Heart Journal
21. Why Is This Subgroup Different from All Other Subgroups? Thoughts on Regional Differences in Randomized Clinical Trials
    Janet Turk Wittes · 2012 · Lecture notes in statistics
22. Task Force on Practice Guidelines A Report of the American College of Cardiology Foundation/American Heart Association 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction:
    David Xiao-Ming Zhao, Jan Radford, Jacqueline E. Tamis‐Holland, Carl L. Tommaso, Cynthia M. Tracy, Jane A. Linderbaum, David A. Morrow, Laura Kristin Newby, Joseph P. Ornato, Francis M. Fesmire et al. · 2014
23. Practical experience with ticagrelor: an Australian and New Zealand perspective
    Scott A. Harding, William Joseph van Gaal, Ryan G. Schrale, Athula P. Gunasekara, John V. Amerena, C. Mussap, Philip E. Aylward · 2015 · Current Medical Research and Opinion
24. Antiplatelet therapy in acute coronary syndromes
    Alberto Menozzi, Daniela Lina, Giulio Conte, Francesco Mantovani, Diego Ardissino · 2011 · Expert Opinion on Pharmacotherapy
25. Impact of aspirin dose on adenosine diphosphate-mediated platelet activities
    Antonio Tello‐Montoliu, Estela Thano, Fabiana Rollini, Ronakkumar Patel, Ryan E. Wilson, Ana Muñiz‐Lozano, Francesco Franchi, Andrew Darlington, Bhaloo Desai, Luis A. Guzmán et al. · 2013 · Thrombosis and Haemostasis
26. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction
    Elaine Nguyen, Erin R. Weeda, Charles Michael White · 2015 · The Journal of Clinical Pharmacology
27. Aspirin
    Carlo Patrono · 2019 · Elsevier eBooks
28. The Platelet P2 Receptors
    Marco Cattaneo · 2019 · Elsevier eBooks
29. Optimal Aspirin Dose in Acute Coronary Syndromes: an Emerging Consensus
    James J. DiNicolantonio, Nicholas B. Norgard, Pascal Meier, Carl J. Lavie, James Henry O’Keefe, Asfandyar Khan Niazi, Saurav Chatterjee, Kathleen A. Packard, Fabrizio D’Ascenzo, Enrico Cerrato et al. · 2014 · Future Cardiology
30. Aspirin for Heart Failure
    John G.F. Cleland, Sunaina Parsons · 2014 · Circulation Heart Failure
31. Update on Interventional Cardiology
    José M. de la Torre Hernández, José Francisco Díaz Fernández, Manel Sabaté, Javier Goicolea Ruigómez · 2013 · Revista Española de Cardiología (English Edition)
32. Comparison of the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome after risk stratification
    Xiaoying Li, Miaohan Qiu, Kun Na, Yuzhuo Li, Sicong Ma, Zizhao Qi, Jing Li, Yi Li, Yaling Han · 2021 · Catheterization and Cardiovascular Interventions
33. Anticoagulation and antiplatelet therapy in acute coronary syndromes
    Dhssraj Singh, Kamal Gupta, James L. Vacek · 2014 · Cleveland Clinic Journal of Medicine
34. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons Endorsed by the American Association for Clinical Chemistry WRITING COMMITTEE MEMBERS*
    Ezra A. Amsterdam, NANETTE KASS WENGER, Ralph G. Brindis, Donald E. Casey, Théodore G. Ganiats, David R. Holmes, Allan S. Jaffe, Hani M. Jneid, Rosemary F. Kelly, Michael Christopher Kontos et al. · 2014
35. Aspirin withdrawal in patients treated with ticagrelor presenting with non‐ST elevation myocardial infarction
    Roy Beigel, Israel Mazin, Edward Koifman, Michael Shechter, Hanna Pres, N. Shlomo, Nurit Rosenberg, Elad Asher, Shlomi Matetzky · 2018 · Journal of Thrombosis and Haemostasis
36. Ticagrelor in Patients With Acute Coronary Syndromes and Stroke
    Stefan Karl James, Karen S. Pieper, Christopher Paul Cannon, Robert F. Storey, Richard Clinton Becker, Philippe Gabríel Steg, Lars C. Wallentin, Robert A. Harrington, for the PLATO study group · 2013 · Stroke
37. Evaluating the Risk-Benefit Profile of the Direct-Acting P2Y12Inhibitor Ticagrelor in Acute Coronary Syndromes
    Steen Husted · 2011 · Postgraduate Medicine
38. Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
    Estella M. Davis, Jon T. Knezevich, Robyn M. Teply · 2013 · Clinical Pharmacology Advances and Applications
39. Antiplatelet therapy: present status and its future directions
    Kaza Ahluwalia, Sangeeta Bhanwra · 2014 · International Journal of Basic & Clinical Pharmacology
40. Clopidogrel instead of prasugrel or ticagrelor after 1 month in stabilized ACS patients: back to square one for DAPT?
    Peter Sinnaeve, Frans Van de Werf · 2017 · European Heart Journal
41. Exploration of the regional effects of colchicine in the LoDoCo2 trial
    Charley Ann Budgeon, Stefan Mark Nidorf, Arend Mosterd, Aernoud T.L. Fiolet, John W. Eikelboom, Sean O’Halloran, David Joyce, Astrid Schut, Jan G.P. Tijssen, Jan Hein Cornel et al. · 2024 · American Heart Journal
42. Recent advances in antithrombotic therapy after acute coronary syndrome
    Alexis Matteau, Deepak L. Bhatt · 2013 · Canadian Medical Association Journal
43. Efficacy and Safety of Clopidogrel Versus Ticagrelor as Part of Dual Antiplatelet Therapy in Acute Coronary Syndrome—A Systematic Review and Meta-analysis
    Niklas Bergh, Anna Myredal, Per Nivedahl, Max Petzold, Sultan Zarin, Constanze Wartenberg, Susanna M. Wallerstedt · 2022 · Journal of Cardiovascular Pharmacology
44. Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor
    Stefano De Servi, Eliano Pio Navarese, Maurizio DʼUrbano, Stefano Savonitto · 2011 · Current Medical Research and Opinion
45. Recruitment of Study Participants
    Lawrence M. Friedman, Curt Daniel Furberg, David L. DeMets, David M. Reboussin, Christopher Bull Granger · 2015 · Springer eBooks
46. Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events
    Aung Myat, Udaya S. Tantry, Jacek Kubica, Paul A. Gurbel · 2016 · Expert Review of Cardiovascular Therapy
47. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
    Wen-Han Feng, Yong-Chieh Chang, Yi‐Hsiung Lin, Hsiao‐Ling Chen, Hsiu-Mei Chang, Chih‐Sheng Chu · 2022 · International Journal of Molecular Sciences
48. Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration
    Fareed A. Awan, Andrew B. Becker, Yuetong Wang, Jonathan Kimmelman · 2022 · Annals of Internal Medicine
49. Ticagrelor versus Adjusted‐Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention
    Ming‐Lung Tsai, Yuan Lin, Dong‐Yi Chen, Ming‐Shyan Lin, Chao‐Yung Wang, Ching‐Lin Hsieh, Ning‐I Yang, Ming‐Jui Hung, Tien‐Hsing Chen · 2024 · Clinical Pharmacology & Therapeutics
50. [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
    Emilio Molina-Cuadrado, Héctor Mateo‐Carrasco, Pablo Nieto-Guindo, Patricia Rodríguez-Gómez · 2014 · PubMed
51. Management of Acute Coronary Syndrome in the Hospital: A Focus on ACCF/AHA Guideline Updates to Oral Antiplatelet Therapy
    Fabian Vengoechea · 2014 · Hospital Practice
52. Updating an Institutional Chest Pain Algorithm
    Gregg F. Rosner, Gregg W. Stone, Jennifer A. Stant, Jennifer M. Burr, Amelia Tirado, Michael Collins, Jeffrey W. Moses, Martin B. Leon, James F. Giglio, LeRoy E. Rabbani · 2012 · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine
53. Actualización en cardiopatía isquémica
    Antonio Fernández‐Ortíz, Javier Jiménez‐Candil, Vicente Bodı́, José A. Barrabés · 2012 · Revista Española de Cardiología
54. Novel Dual Therapy: A Paradigm Shift in Anticoagulation in Patients of Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
    Akshyaya Kumar Pradhan, Monika Bhandari, Pravesh Vishwakarma, Rishi Sethi · 2020 · TH Open
55. Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
    Andrew Kei‐Yan Ng, Pauline Yeung Ng, April Ip, Kui Kai Lau, Chung‐Wah Siu · 2022 · Stroke and Vascular Neurology
56. Safety profile and bleeding risk of ticagrelor compared with clopidogrel
    Christopher H. May, Abraham Michael Lincoff · 2012 · Expert Opinion on Drug Safety
57. Exposure‐Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction
    Daniel Röshammar, Joakim Nyberg, Tomas Andersson, Donald R. Stanski, Robert F. Storey, Bengt Hamrén · 2016 · The Journal of Clinical Pharmacology
58. Refuting the Ticagrelor-Aspirin Black Box Warning: And Proposing a Ticagrelor Early-PCI Black Box Warning
    James J. DiNicolantonio, Victor L. Serebruany, Aleš Tomek · 2013 · International Journal of Cardiology
59. How country-specific should a country-specific cost-effectiveness analysis be?
    Shelby D. Reed · 2012 · European Heart Journal
60. The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy
    Timothy David Warner, Paul C. J. Armstrong, Melissa V. Chan, Rebecca Knowles · 2016 · Expert Review of Hematology
61. Globalization of heart failure trials: no turning back on this paradigm
    Faiez M. Zannad, João Pedro Ferreira · 2016 · European Heart Journal
62. Percutaneous Coronary Intervention
    Dharam J. Kumbhani, Deepak L. Bhatt · 2012
63. Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
    Davis Brent Jones, Johny Nicolas, Frans Beerkens, Mohan Satish, Daniel Feldman, Davide Cao, Alessando Spirito, Roxana Mehran · 2022 · Reviews in Cardiovascular Medicine
64. Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS)
    Sigrid E. Sandner, Mario F.L. Gaudino, Stefan Agewall, Giorgia Bonalumi, Nikolaos E. Bonaros, Martin Czerny, Anders Jeppsson, Milan Milojevic, Alexander Niessner, Alessandro Parolari et al. · 2025 · European Journal of Cardio-Thoracic Surgery
65. Cost-Effectiveness of Aortic Valve Replacement in Low- and Intermediate-Risk Chinese Patients With Severe Aortic Stenosis
    Jin Peng, Xinglong Zheng, Minghuan Jiang, Xuelin Yao, Yue Ma, Mao Fu, Tao Ma, Xiaolong Shang, Yan Xia Yang, Vinod H. Thourani et al. · 2025 · Circulation Cardiovascular Quality and Outcomes
66. Monitoring of Antiplatelet Therapy
    Paul Alfred Gurbel, Udaya S. Tantry · 2012 · Elsevier eBooks
67. Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction
    Yongwhi Park, Francesco Franchi, Fabiana Rollini, Dominick Joseph Angiolillo · 2015 · Trends in Cardiovascular Medicine
68. Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes
    Doron Aronson · 2014 · Thrombosis and Haemostasis
69. Contemporary management of ST-segment elevation myocardial infarction
    Ajay Yadlapati, Mark M. Gajjar, Daniel R. Schimmel, Mark J. Ricciardi, James D. Flaherty · 2016 · Internal and Emergency Medicine
70. Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review
    Daniel Caldeira, Hélder Pereira · 2019 · Revista Portuguesa de Cardiologia
71. Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes
    Abhizith Deoker, Angelica Lehker, Debabrata Mukherjee · 2020 · Current Cardiology Reports
72. Regional variation in patients and outcomes in the GLOBAL LEADERS trial
    Chao Gao, Kuniaki Takahashi, Scot Garg, Hironori Hara, Rutao Wang, Hideyuki Kawashima, Masafumi Ono, Gilles Montalescot, Michael Haude, Ton Slagboom et al. · 2020 · International Journal of Cardiology
73. Ticagrelor Use in Stroke Patients: Past, Present, and Future
    Rahul Chandra, Harneel Saini, Russell Cerejo, Ashis H. Tayal, Konark Malhotra · 2021 · Vascular Health and Risk Management
74. The Year in Interventional Cardiology
    Simon R. Dixon, Robert D. Safian · 2012 · Journal of the American College of Cardiology
75. Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review
    Rajkumar Prakashbhai Doshi, Abhishek Vadher, Priyam Mithawala, Priyank Shah · 2018 · Irish Journal of Medical Science (1971 -)
76. Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease—A meta-analysis of randomized clinical trials
    Salvatore Cassese, Gjin Ndrepepa, Robert A. Byrne, Karl‐Ludwig Laugwitz, Heribert Schunkert, Massimiliano Fusaro, Fernándo Alfonso, Adnan Kastrati · 2019 · American Heart Journal
77. Duale Plättchenhemmung in der Intensivmedizin
    Jolanta Maria Siller-Matula, Georg Delle Karth · 2014 · Medizinische Klinik - Intensivmedizin und Notfallmedizin
78. Cost–effectiveness of ticagrelor in acute coronary syndromes
    Martin Henriksson, Magnus Janzon · 2013 · Expert Review of Pharmacoeconomics & Outcomes Research
79. Most Important Outcomes Research Papers on Variation in Cardiovascular Disease
    Julianna F. Lampropulos, Aakriti Gupta, Vivek Kulkarni, Purav S. Mody, Ruijun Chen, Behnood Bikdeli, Kumar Dharmarajan, for the Editor · 2013 · Circulation Cardiovascular Quality and Outcomes
80. Stent thrombosis in patients with drug-eluting stents and bioresorbable vascular scaffolds. The feared complication
    Laura S.M. Kerkmeijer, Erhan Tenekecioğlu, Joanna J. Wykrzykowska · 2018 · Polskie Archiwum Medycyny Wewnętrznej
81. Nuevas evidencias sobre la antiagregación para el síndrome coronario agudo sin elevación del ST
    Alberto Cecconi, David Vivas, Antonio Fernández‐Ortíz · 2014 · Revista Española de Cardiología Suplementos
82. Actualización en cardiología intervencionista
    José M. de la Torre Hernández, José Francisco Díaz Fernández, Manel Sabaté, Javier Goicolea Ruigómez · 2013 · Revista Española de Cardiología
83. Ticagrelor Paradox: Systematic Review and Network Meta‐Analysis
    Atsuyuki Watanabe, Tadao Aikawa, Yoshihisa Miyamoto, Hiroki A. Ueyama, Tomohiro Fujisaki, Satoshi Shoji, Kaveh Hosseini, Leandro N. Slipczuk, Αlexandros Briasoulis, Polydoros Ν. Kampaktsis et al. · 2025 · Journal of the American Heart Association
84. Trials Evaluating Ticagrelor in Cardiovascular Disease: Will It Reign Supreme in the Anti-Platelet World?
    Cheuk Kit Wong · 2017 · Cardiovascular Pharmacology Open Access
85. Review of ticagrelor in the management of acute coronary syndromes
    Sonya N. Burgess, Trevor Mallard, C. Juergens · 2012 · Expert Opinion on Drug Metabolism & Toxicology
86. Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations
    James C. Coons, Taylor J. Miller · 2014 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
87. Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response
    Richard Good, Anne M. McGarrity, Tina E. James, H. Miller, Alex McConnachie, Alison H. Goodall, Keith G. Oldroyd · 2015 · Thrombosis Research
88. P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use
    Nicholas B. Norgard, James J. DiNicolantonio · 2015 · Therapeutic Advances in Chronic Disease
89. Unravelling the benefit against the risk of long-term dual antiplatelet therapy
    Leonardo Bolognese, Dominick Joseph Angiolillo · 2011 · Current Opinion in Cardiology
90. Duration of Dual Antiplatelet Therapy in Coronary Artery Disease: a Review Article
    Alex D. Moseley, F. Collado, Annabelle Santos Volgman, Gary L. Schaer, R. Jeffrey Snell · 2016 · Current Atherosclerosis Reports
91. Successful coronary stenting in a patient with factor V deficiency in the absence of fresh frozen plasma transfusion
    Seong Il Choi, MooKon Song · 2017 · Medicine
92. Sex Differences in Platelet Reactivity in Patients With ST-Elevation Myocardial Infarction: A Sub-Analysis of the ON-TIME 3 Trial
    Anne H. Tavenier, Renicus Suffridus Hermanides, Jan Paul Ottervanger, Svetlana V. Belitser, Olaf H. Klungel, Yolande Appelman, Maarten A.H. van Leeuwen, Arnoud W.J. van ’t Hof · 2021 · Frontiers in Cardiovascular Medicine
93. Novel Antiplatelet Agents in Cardiovascular Medicine
    Rahil Rafeedheen, Kevin P. Bliden, Fang Liu, Udaya S. Tantry, Paul Alfred Gurbel · 2015 · Current Treatment Options in Cardiovascular Medicine
94. The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease
    Paul P. Dobesh, Manesh R. Patel · 2017 · Cardiovascular Drugs and Therapy
95. Novel Antiplatelet Therapies
    Kumaran Kolandaivelu, Deepak L. Bhatt · 2019 · Elsevier eBooks
96. Current therapy of non-ST-elevation acute coronary syndromes.
    George Paxinos, Demosthenes G. Katritsis · 2012 · PubMed
97. Does geographical variability influence five-year MACCE rates in the multicentre SYNTAX revascularisation trial?
    Andrew K. Roy, Bernard Chevalier, Thierry Lefèvre, Yves Louvard, Ricardo Segurado, Fadi Sawaya, Marco Spaziano, Antoinette M. Neylon, Patrick W.J.C. Serruys, Keith D. Dawkins et al. · 2017 · EuroIntervention
98. P2Y12 Antagonists
    Marco Cattaneo · 2019 · Elsevier eBooks
99. Exploring PLATO-USA Paradox and CURRENT-OASIS 7 Trials Reveals the Benefit of Higher Aspirin Dose
    James J. DiNicolantonio, Victor L. Serebruany · 2013 · American Journal of Therapeutics
100. Impact of the reporting source on Platelet Inhibition and Treatment Outcomes (PLATO) trial deaths
     Victor L. Serebruany, Jean‐François Tanguay, Héctor A. Cabrera-Fuentes, Milana L. Gurvich, Thomas A. Marciniak, Bethany Beach, Delaware, USA · 2023 · Discoveries